This template was built with Webflow's free Prospero UI Kit. Learn more
An SCN2A variant is usually a small error inside a very long set of instructions. In most children, the difference between a sodium channel that works and one that misfires comes down to a handful of genetic letters. Sometimes it comes down to one.
Researchers built prime editing to fix exactly that kind of error.
For several years this belonged in the category of interesting but distant science. That has changed. Within the past eighteen months, prime editing has corrected a genetic disease in a living person, repaired a disease-causing mutation inside a living brain, and been applied to two real SCN2A variants in human cells.
Here is what has actually been achieved, and what still has to happen.
Prime editing is a gene-editing tool that rewrites a specific piece of DNA without cutting both strands. A guide molecule called a pegRNA carries both the error's address and the correction itself. Researchers have used it to correct SCN2A variants in human stem cells.
Standard CRISPR is often described as a GPS attached to a pair of scissors. It finds an address, and it cuts.
Prime editing works on a different principle. The pegRNA, short for prime editing guide RNA, does two jobs at once. It specifies the target site, and it carries the desired correction written into its own sequence. The tool arrives at the right address already holding the replacement text.
Two proteins do the work. A Cas9 nickase is a CRISPR protein deliberately weakened so that it can only nick one strand of DNA rather than sever both. A reverse transcriptase is an enzyme that writes new DNA using the pegRNA as its template.
The 2019 paper that introduced the technology described it as search-and-replace genome editing.
The first CRISPR tools cut through both strands of the DNA double helix. The cell stitches that break back together on its own, and it sometimes adds or loses a few genetic letters along the way. That works well when the goal is to switch a gene off. It is harder to control when the goal is one exact correction.
Prime editing nicks one strand and leaves the other intact as a scaffold. Researchers describe this as the central safety advantage of the approach. It is a large part of why teams working on brain disorders have paid close attention.
We cover a closely related technology in our guide to SCN2A base editing.
SCN2A carries the instructions for part of a sodium channel called Nav1.2, which controls how brain cells generate and pass along electrical signals. We explain what SCN2A does in the brain in more detail separately.
Most families first learn their child’s variant through a functional label. Gain-of-function (GOF) variants leave the channel overactive. Loss-of-function (LOF) variants leave it underactive or absent. Mixed-function variants do some of both.
When choosing an editing tool, a different question matters more. What is the physical shape of the genetic change?
Many SCN2A variants are single-letter swaps, known as missense variants. A meaningful number are changes where letters are missing, letters are added where they don't belong, or the reading frame shifts out of alignment from that point onward. We break these down in our guide to the different SCN2A mutation types.
This is where prime editing becomes interesting across the whole community. This foundational prime editing paper from David Liu's lab at the Broad Institute, reported targeted insertions, targeted deletions, and all twelve possible types of point mutations, without double-strand breaks and without donor DNA templates. Other editing tools are limited to four of those twelve swaps and cannot add or remove letters at all.
Prime editing is not restricted in that way. In principle, its mechanism applies to GOF, LOF, and mixed function variants alike, because it responds to the shape of the change rather than its functional direction.
That is a mechanistic argument, not a demonstrated result for every variant. Each edit still has to be designed for its specific site, and some sites are far easier to reach than others. But the tool itself is not built for one kind of family.
In December 2025, the New England Journal of Medicine published the first clinical results from a prime editing therapy.
The condition was chronic granulomatous disease, an inherited immune disorder caused in many cases by two missing DNA letters in a gene called NCF1. Researchers collected blood stem cells from two participants, corrected the deletion with prime editing outside the body, and returned the corrected cells.
Both participants engrafted promptly. Their neutrophils showed the immune enzyme activity they had been missing within one month, and they sustained it through the last reported follow-up visit: six months for the first participant and four months for the second. Their adverse events matched the conditioning regimen they received before the infusion.
Two people. A different disease. Cells edited in a dish rather than inside the body. All of that is accurate, and none of it diminishes what happened.
Prime editing is no longer a laboratory technique waiting for its first patient. It has corrected a genetic disease in a human being.
The harder question for SCN2A families is whether any of this can happen in neurons, which cannot be removed, corrected, and put back. Two results from the past two years say that it can.
In 2026, a team at the University of Zurich published work in Science Translational Medicine on SCN1A, a sibling sodium channel gene. Their mouse model carried the K1270T variant, the same change found in people with generalized epilepsy with febrile seizures plus.
The researchers packaged a prime editor into viral vectors and delivered it into the brain ventricles of newborn mice. The editor corrected the disease-causing mutation in most nerve cells in a key brain region.
The effect on seizures was striking. Roughly 80% of animals in the control group developed fever-induced seizures. Among treated animals, that figure dropped to roughly 15%. Survival improved markedly, and signaling between nerve cells improved as well.
This was a mouse, a different gene, and treatment delivered shortly after birth. It was also the first published demonstration that gene editing can correct a disease-causing mutation directly inside the brain in an inherited epilepsy.
In 2025, a separate team reported prime editing strategies for ATP1A3, the gene responsible for roughly 70% of childhood alternating hemiplegia cases. In human cells, they corrected five prevalent mutations with efficiencies ranging from 43% to 90%.
The animal work went further. Delivered by AAV into the brains of two mouse models, prime editing produced up to 48% DNA correction and 73% messenger RNA correction in bulk brain cortex. Treated animals showed improved paroxysmal spells, motor deficits, and cognitive measures, along with a substantial extension of lifespan.
The authors describe their results as establishing that prime editing can rescue a neurological disease in animals.
Y Lab - a research group at Purdue University has been applying prime editing directly to SCN2A. They presented their work at the American Epilepsy Society annual meeting in both 2024 and 2025.
The 2024 presentation carried something significant for the full SCN2A community. Using an all-RNA prime editing platform, the lab created and then corrected two different SCN2A variants in human induced pluripotent stem cells: L1342P, which prior work describes as showing predominantly gain-of-function features, and Y84X, a truncating variant. The reported outcome was promising editing efficiency with minimal off-target effects. The authors did not report a specific efficiency figure for either variant.
The 2025 presentation reported numbers. Prime editing at the L1342P site in stem cells reached efficiencies ranging from 20% to 67%, depending on the specific design, guide RNA position, and whether the team inhibited mismatch repair. The same work separately characterized uncorrected L1342P brain organoids and found pronounced hyperexcitability.
Both of these are conference abstracts rather than peer-reviewed publications. The next milestone is demonstrating that correction restores neuronal function, and the authors have stated that as their explicit aim for future work.
This amounts to an active program producing results. SCN2A now sits roughly where SCN1A and ATP1A3 sat a few years before their in-brain results arrived.
.jpg)
The remaining path is visible, not hypothetical.
Researchers need to show that corrected SCN2A cells grow into neurons that behave like healthy neurons. Animal models carrying SCN2A variants are needed to test correction inside a living brain. And delivery has to scale from a newborn mouse to a human child, which remains the hardest unsolved problem in the field.
None of that is minor. All of it has now been accomplished for other genes.
Researchers have corrected SCN2A variants in human stem cells grown in a laboratory. No SCN2A prime editing therapy has been tested in an animal carrying an SCN2A variant or in a person, and no clinical trial exists.
Yes. The first clinical results were published in December 2025 in two participants with chronic granulomatous disease, a different genetic condition. That work involved editing blood stem cells outside the body.
Prime editing nicks one DNA strand rather than cutting both, which researchers describe as its central safety rationale. Early human data have been encouraging. Long-term safety across many patients remains unestablished.
Its mechanism does not depend on the variant's functional direction, and researchers have applied it to both a gain-of-function SCN2A variant and a truncating variant in human cells. Whether researchers can correct an individual variant depends on the design at that site.
Gene correction programs need one thing before they can reach children. They need a community that researchers can find, describe, and enroll. You can help build that in three steps.
Add your family to the SCN2A WorldMap. It is a privacy-first global map of families affected by SCN2A-related disorders, built to make this community visible to clinicians, regulators, and industry partners. Registration takes about 90 seconds, and location is stored at city level only.
Then join the SCN2A patient registry. When a trial opens, the variants and the families have to already be documented. The registry is what makes that possible.
Every family navigating an SCN2A diagnosis deserves answers and a path forward. The research described in this article exists because people chose to fund it. Please consider making a donation to help fund the work that moves all of us closer to a treatment.
Medical Disclaimer: This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Share
An SCN2A variant is usually a small error inside a very long set of instructions. In most children, the difference between a sodium channel that works and one that misfires comes down to a handful of genetic letters. Sometimes it comes down to one.
Researchers built prime editing to fix exactly that kind of error.
For several years this belonged in the category of interesting but distant science. That has changed. Within the past eighteen months, prime editing has corrected a genetic disease in a living person, repaired a disease-causing mutation inside a living brain, and been applied to two real SCN2A variants in human cells.
Here is what has actually been achieved, and what still has to happen.
Prime editing is a gene-editing tool that rewrites a specific piece of DNA without cutting both strands. A guide molecule called a pegRNA carries both the error's address and the correction itself. Researchers have used it to correct SCN2A variants in human stem cells.
Standard CRISPR is often described as a GPS attached to a pair of scissors. It finds an address, and it cuts.
Prime editing works on a different principle. The pegRNA, short for prime editing guide RNA, does two jobs at once. It specifies the target site, and it carries the desired correction written into its own sequence. The tool arrives at the right address already holding the replacement text.
Two proteins do the work. A Cas9 nickase is a CRISPR protein deliberately weakened so that it can only nick one strand of DNA rather than sever both. A reverse transcriptase is an enzyme that writes new DNA using the pegRNA as its template.
The 2019 paper that introduced the technology described it as search-and-replace genome editing.
The first CRISPR tools cut through both strands of the DNA double helix. The cell stitches that break back together on its own, and it sometimes adds or loses a few genetic letters along the way. That works well when the goal is to switch a gene off. It is harder to control when the goal is one exact correction.
Prime editing nicks one strand and leaves the other intact as a scaffold. Researchers describe this as the central safety advantage of the approach. It is a large part of why teams working on brain disorders have paid close attention.
We cover a closely related technology in our guide to SCN2A base editing.
SCN2A carries the instructions for part of a sodium channel called Nav1.2, which controls how brain cells generate and pass along electrical signals. We explain what SCN2A does in the brain in more detail separately.
Most families first learn their child’s variant through a functional label. Gain-of-function (GOF) variants leave the channel overactive. Loss-of-function (LOF) variants leave it underactive or absent. Mixed-function variants do some of both.
When choosing an editing tool, a different question matters more. What is the physical shape of the genetic change?
Many SCN2A variants are single-letter swaps, known as missense variants. A meaningful number are changes where letters are missing, letters are added where they don't belong, or the reading frame shifts out of alignment from that point onward. We break these down in our guide to the different SCN2A mutation types.
This is where prime editing becomes interesting across the whole community. This foundational prime editing paper from David Liu's lab at the Broad Institute, reported targeted insertions, targeted deletions, and all twelve possible types of point mutations, without double-strand breaks and without donor DNA templates. Other editing tools are limited to four of those twelve swaps and cannot add or remove letters at all.
Prime editing is not restricted in that way. In principle, its mechanism applies to GOF, LOF, and mixed function variants alike, because it responds to the shape of the change rather than its functional direction.
That is a mechanistic argument, not a demonstrated result for every variant. Each edit still has to be designed for its specific site, and some sites are far easier to reach than others. But the tool itself is not built for one kind of family.
In December 2025, the New England Journal of Medicine published the first clinical results from a prime editing therapy.
The condition was chronic granulomatous disease, an inherited immune disorder caused in many cases by two missing DNA letters in a gene called NCF1. Researchers collected blood stem cells from two participants, corrected the deletion with prime editing outside the body, and returned the corrected cells.
Both participants engrafted promptly. Their neutrophils showed the immune enzyme activity they had been missing within one month, and they sustained it through the last reported follow-up visit: six months for the first participant and four months for the second. Their adverse events matched the conditioning regimen they received before the infusion.
Two people. A different disease. Cells edited in a dish rather than inside the body. All of that is accurate, and none of it diminishes what happened.
Prime editing is no longer a laboratory technique waiting for its first patient. It has corrected a genetic disease in a human being.
The harder question for SCN2A families is whether any of this can happen in neurons, which cannot be removed, corrected, and put back. Two results from the past two years say that it can.
In 2026, a team at the University of Zurich published work in Science Translational Medicine on SCN1A, a sibling sodium channel gene. Their mouse model carried the K1270T variant, the same change found in people with generalized epilepsy with febrile seizures plus.
The researchers packaged a prime editor into viral vectors and delivered it into the brain ventricles of newborn mice. The editor corrected the disease-causing mutation in most nerve cells in a key brain region.
The effect on seizures was striking. Roughly 80% of animals in the control group developed fever-induced seizures. Among treated animals, that figure dropped to roughly 15%. Survival improved markedly, and signaling between nerve cells improved as well.
This was a mouse, a different gene, and treatment delivered shortly after birth. It was also the first published demonstration that gene editing can correct a disease-causing mutation directly inside the brain in an inherited epilepsy.
In 2025, a separate team reported prime editing strategies for ATP1A3, the gene responsible for roughly 70% of childhood alternating hemiplegia cases. In human cells, they corrected five prevalent mutations with efficiencies ranging from 43% to 90%.
The animal work went further. Delivered by AAV into the brains of two mouse models, prime editing produced up to 48% DNA correction and 73% messenger RNA correction in bulk brain cortex. Treated animals showed improved paroxysmal spells, motor deficits, and cognitive measures, along with a substantial extension of lifespan.
The authors describe their results as establishing that prime editing can rescue a neurological disease in animals.
Y Lab - a research group at Purdue University has been applying prime editing directly to SCN2A. They presented their work at the American Epilepsy Society annual meeting in both 2024 and 2025.
The 2024 presentation carried something significant for the full SCN2A community. Using an all-RNA prime editing platform, the lab created and then corrected two different SCN2A variants in human induced pluripotent stem cells: L1342P, which prior work describes as showing predominantly gain-of-function features, and Y84X, a truncating variant. The reported outcome was promising editing efficiency with minimal off-target effects. The authors did not report a specific efficiency figure for either variant.
The 2025 presentation reported numbers. Prime editing at the L1342P site in stem cells reached efficiencies ranging from 20% to 67%, depending on the specific design, guide RNA position, and whether the team inhibited mismatch repair. The same work separately characterized uncorrected L1342P brain organoids and found pronounced hyperexcitability.
Both of these are conference abstracts rather than peer-reviewed publications. The next milestone is demonstrating that correction restores neuronal function, and the authors have stated that as their explicit aim for future work.
This amounts to an active program producing results. SCN2A now sits roughly where SCN1A and ATP1A3 sat a few years before their in-brain results arrived.
The remaining path is visible, not hypothetical.
Researchers need to show that corrected SCN2A cells grow into neurons that behave like healthy neurons. Animal models carrying SCN2A variants are needed to test correction inside a living brain. And delivery has to scale from a newborn mouse to a human child, which remains the hardest unsolved problem in the field.
None of that is minor. All of it has now been accomplished for other genes.
Researchers have corrected SCN2A variants in human stem cells grown in a laboratory. No SCN2A prime editing therapy has been tested in an animal carrying an SCN2A variant or in a person, and no clinical trial exists.
Yes. The first clinical results were published in December 2025 in two participants with chronic granulomatous disease, a different genetic condition. That work involved editing blood stem cells outside the body.
Prime editing nicks one DNA strand rather than cutting both, which researchers describe as its central safety rationale. Early human data have been encouraging. Long-term safety across many patients remains unestablished.
Its mechanism does not depend on the variant's functional direction, and researchers have applied it to both a gain-of-function SCN2A variant and a truncating variant in human cells. Whether researchers can correct an individual variant depends on the design at that site.
Gene correction programs need one thing before they can reach children. They need a community that researchers can find, describe, and enroll. You can help build that in three steps.
Add your family to the SCN2A WorldMap. It is a privacy-first global map of families affected by SCN2A-related disorders, built to make this community visible to clinicians, regulators, and industry partners. Registration takes about 90 seconds, and location is stored at city level only.
Then join the SCN2A patient registry. When a trial opens, the variants and the families have to already be documented. The registry is what makes that possible.
Every family navigating an SCN2A diagnosis deserves answers and a path forward. The research described in this article exists because people chose to fund it. Please consider making a donation to help fund the work that moves all of us closer to a treatment.
Medical Disclaimer: This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Vlad Magdalin
Accelerating research and treatment for SCN2A-related disorders.
Get the latest SCN2A research and community news.